Le Lézard
Classified in: Health, Business
Subjects: LAW/LEGAL ISSUES, SHAREHOLDER RIGHTS PLANS

NYMOX REPORTS: Bahamian Court Today Suspends Order of October 3, 2023 Rendering Riley-Lanham and Accomplices Planned Vote Unauthorized


IRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation ("Nymox" or the "Company") [OTC Markets---NYMXF] is pleased to announce that the Bahamian Court (Senior Justice Deborah Fraser) today issued an oral ruling suspending the Ex Parte Order of October 3, 2023 wrongly obtained by the so called activist shareholders led by Mr. Lanham. Senior Justice Fraser accepted Nymox's arguments that justice would best be served with the order suspended.

In the Bahamas, Nymox will continue now to formally set aside the Ex Parte Order, and will be seeking from Mr. Lanham and his accomplices payment of both its legal costs, and separately, damages suffered by Nymox and its directors arising from the wrongful procurement of the Ex Parte Order.

For more information please contact [email protected] or 800-936-9669.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2022, and its Quarterly Reports.

For Further Information Contact:
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com



These press releases may also interest you

at 08:54
Baldoria Vermouth, a leading contemporary vermouth brand, is pleased to announce its latest strategic partnership: a collaboration agreement with Caffè Moak, a notable Italian coffee roaster and global distributor headquartered in Modica, Sicily....

at 08:54
Bybit, the world's second-largest cryptocurrency exchange by trading volume, spotlights altcoins in a  report jointly released with Block Scholes, offering insights on factors that may have delayed the arrival of an altcoin boom. Titled "Altcoin...

at 08:50
ModelOp, the leading AI Governance software for enterprises, is pleased to announce the appointment of Mitch Tompkins as its new VP of Sales. With his customer-centric sales approach and a proven track record in driving revenue growth,...

at 08:47
Vitazi.ai, Inc., a key leader in Oculomics, is pleased to announce an agreement with Eye Associates of New Mexico, the largest ophthalmology organization in the state. Eye Associates sees between 1400 and 1500 patients daily at its 11 clinics...

at 08:47
1st Commercial Credit, LLC, a trusted factoring company with over 22 years of experience, is excited to introduce its 2nd Position Factoring program. This innovative financing solution is tailored for businesses with an existing bank term loan that...

at 08:45
24 Seven, one of the nation's largest privately held marketing, creative, and digital talent solutions firms, today announced the acquisition of CORE Resources, a leading provider of technology talent solutions to Canada's financial services sector....



News published on and distributed by: